Bijak Michal, Ponczek Michal Blazej, Nowak Pawel
Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Department of General Biochemistry, Faculty of Biology and Environmental Protection, University of Lodz, Pomorska 141/143, 90-236 Lodz, Poland.
Int J Biol Macromol. 2014 Apr;65:129-35. doi: 10.1016/j.ijbiomac.2014.01.023. Epub 2014 Jan 18.
Blood coagulation consists of series of zymogens which can be converted by limited proteolysis to active enzymes leading to the generation of thrombin and conversion of fibrinogen into fibrin by this enzyme. The activated factor X (FXa) forms prothrombinase complex on phosphatidylserine containing surface which is responsible for conversion of prothrombin to thrombin. One molecule of FXa generates more than 1000 thrombin molecules. Therefore FXa is a novel target for modern anticoagulant therapy. The aim of our present study is to examine the effects of the well-known plant polyphenolic compounds on factor Xa amidolytic activity and characterization of these interactions using bioinformatic ligand docking method. We observed that only four polyphenols belonging to flavonoids group: procyanidin B2, cyanidin, quercetin and silybin, had inhibitory effect on FXa activity. Bioinformatic analyses revealed that procyanidin B2, cyanidin, quercetin and silybin bound in the S1-S4 pockets located in vicinity of the FXa active site and blocked access of substrates to Ser195. The results presented here showed that flavonoids might be potential structural bases for design of new nature-based, safe, orally bioavailable direct FXa inhibitors.
血液凝固由一系列酶原组成,这些酶原可通过有限的蛋白水解作用转化为活性酶,从而导致凝血酶的生成,并使纤维蛋白原在该酶的作用下转化为纤维蛋白。活化的因子X(FXa)在含磷脂酰丝氨酸的表面形成凝血酶原酶复合物,该复合物负责将凝血酶原转化为凝血酶。一个FXa分子可产生1000多个凝血酶分子。因此,FXa是现代抗凝治疗的一个新靶点。我们目前研究的目的是使用生物信息学配体对接方法,研究著名的植物多酚化合物对因子Xa酰胺水解活性的影响以及这些相互作用的特征。我们观察到,只有属于黄酮类的四种多酚:原花青素B2、花青素、槲皮素和水飞蓟宾,对FXa活性有抑制作用。生物信息学分析表明,原花青素B2、花青素、槲皮素和水飞蓟宾结合在FXa活性位点附近的S1 - S4口袋中,阻止底物接近丝氨酸195。此处呈现的结果表明,黄酮类化合物可能是设计新型基于天然、安全、口服生物可利用的直接FXa抑制剂的潜在结构基础。